Literature DB >> 7824190

Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices.

C Malgouris1, M Daniel, A Doble.   

Abstract

The neuroprotective activity of riluzole has been studied on N-methyl-D-aspartate (NMDA)- or veratridine-induced toxicity in immature rat hippocampal slices. Neurodegeneration was assessed by the measurement of LDH release and histology. Veratridine-induced LDH release can be inhibited by 100 microM riluzole (-90% and by tetrodotoxin (1 microM). Riluzole markedly reduced (-59%) the NMDA-induced LDH release and this protective effect was confirmed by histology. Riluzole inhibited the NMDA-induced LDH release in the presence of tetrodotoxin. Moreover, a pretreatment with pertussis toxin (1 microgram/ml) abolished the effect of riluzole against NMDA-induced neurotoxicity. These results support the view that the neuroprotective properties of riluzole could be exerted via two distinct mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824190     DOI: 10.1016/0304-3940(94)90053-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

Review 2.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Stronger is not always better: could a bodybuilding dietary supplement lead to ALS?

Authors:  Marin Manuel; C J Heckman
Journal:  Exp Neurol       Date:  2010-12-15       Impact factor: 5.330

4.  Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.

Authors:  G M Ginsberg; B Lev
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

Review 5.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

Review 6.  NMDA receptors in clinical neurology: excitatory times ahead.

Authors:  Lorraine V Kalia; Suneil K Kalia; Michael W Salter
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

7.  Pre-clinical safety and therapeutic efficacy of a plant-based alkaloid in a human colon cancer xenograft model.

Authors:  Jessica L Freeling; Jamie L Scholl; Morgan Eikanger; Cole Knoblich; Rashaun A Potts; David J Anderson; Joseph E Rower; Mohammad Hadi Farjoo; Haotian Zhao; Angela Pillatzki; Khosrow Rezvani
Journal:  Cell Death Discov       Date:  2022-03-28

Review 8.  Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2013-08-09       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.